Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data

Kristian Egebjerg, Tobias Sørup Andersen, Lene Bæksgaard, Rajendra Garbyal, Mette Siemsen, Michael Achiam, Paul Morten Mau-Sørensen*

*Corresponding author for this work

Abstract

BACKGROUND AND PURPOSE: Perioperative 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) is recommended in resectable esophagogastric adenocarcinoma based on randomised trials. However, the effectiveness of FLOT in routine clinical practice remains unknown as randomised trials are subject to selection bias limiting their generalisability. The aim of this study was to evaluate the implementation of FLOT in real-world patients.

METHODS: Retrospectively collected data were analysed in consecutive patients treated before or after the implementation of FLOT. The primary endpoint was complete pathological response (pCR) and secondary endpoints were margin-free resection (R0), overall survival (OS), relapse-free survival (RFS) tolerability of chemotherapy and surgical complications.

RESULTS: Mean follow-up time for patients treated with FLOT (n = 205) was 37.7 versus 47.0 months for epirubicin, cis- or oxaliplatin, and capecitabine (ECX/EOX, n = 186). Surgical resection was performed in 88.0% versus 92.0%; pCR were observed in 3.8% versus 2.4%; and R0 resections were achieved in 78.0% versus 86.0% (p = 0.03) in the ECX/EOX and FLOT cohorts, respectively. Survival analysis indicated no significant difference in RFS (p = 0.17) or OS (p = 0.37) between the cohorts with a trend towards increased OS in performance status 0 (hazard ratio [HR] = 0.73, 95% confidence interval [CI]: 0.50-1.04). More patients treated with ECX/EOX completed chemotherapy (39% vs. 28%, p = 0.02). Febrile neutropenia was more common in the FLOT cohort (3.8% vs. 11%, p = 0.0086). 90-days mortality (1.2% vs. 0%) and frequency of anastomotic leakage (8% vs. 6%) were equal and low.

INTERPRETATION: Patients receiving FLOT did not demonstrate improved pCR, RFS or OS. However, R0 rate was improved and patients in good PS trended towards improved OS.

Original languageEnglish
JournalActa Oncologica
Volume63
Pages (from-to)322-329
Number of pages8
ISSN0284-186X
DOIs
Publication statusPublished - 14 May 2024

Keywords

  • Humans
  • Male
  • Adenocarcinoma/drug therapy
  • Esophageal Neoplasms/drug therapy
  • Female
  • Middle Aged
  • Aged
  • Oxaliplatin/therapeutic use
  • Retrospective Studies
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Capecitabine/administration & dosage
  • Docetaxel/administration & dosage
  • Stomach Neoplasms/drug therapy
  • Fluorouracil/administration & dosage
  • Leucovorin/therapeutic use
  • Epirubicin/administration & dosage
  • Adult
  • Cisplatin/administration & dosage
  • Aged, 80 and over
  • Perioperative Care/methods
  • Esophagogastric Junction/pathology

Fingerprint

Dive into the research topics of 'Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data'. Together they form a unique fingerprint.

Cite this